Candel fell as much as 38% in premarket trading Friday after disclosing its biologics license application for aglatimagene besadenovec in prostate cancer is delayed to mid-2027, from this year, due to assay-refinement timelines in its ongoing FDA talks. The Q3 net loss widened to $21.9 million from $11.3 million a year ago; cash of $203.1 million is expected to fund operations into Q2 2028.
Useful?